Wednesday, 14 May 2014

Cineworld: The O2, London, SE10 0DX, UK

www.regonline.co.uk/anticancer2014

This event will discuss development of therapies for cancer treatment including, but not exclusively biologicals, looking at discoveries in the laboratory to clinical phase trials.  This is not only an ideal place to showcase research and development but also to discover what may become new on the market and to network with experts in the field

This event has CPD accreditation and is part of the

Controlling Cancer Summit 2014 –www.controllingcancersummit2014.com

Meeting Chair: Dr Ann L White, Antibody and Vaccine Group, Faculty of Medicine, Southampton University Hospital, UK

The Deadline for abstract submissions for oral presentation is Feb 10th 2014

Abstracts for poster presentation only can be submitted up to two weeks before the event. You can download the instructions for authors at

www.euroscicon.com/AbstractsForOralAndPosterPresentation.pdf

 Talks include

The selective targeting of cell survival pathways in cancer cells

Dr. Mark Guthridge, Senior Research Fellow, Australian Centre for Blood Diseases, Monash University, Melbourne, Australia

Translating antibodies engineered with IgE Fc regions to elicit enhanced effector functions for cancer therapy

Dr. Sophia N. Karagiannis, Senior Research Fellow in Translational Cancer Immunology, Head of Cancer Antibody Discovery and Immunotherapy, St. John’s Institute of Dermatology, Division of Genetics and Molecular Medicine, King’s College London School of Medicine, UK

Targeting leukemic stem cells to improve treatment of  chronic myeloid leukemia.

Dr. Xiaoyan Jiang, Senior Scientist and Associate Professor, Terry Fox Laboratory,  BC Cancer Agency Medical Genetics, University of British Columbia, Canada